Source: Medicines and Medical Devices Safety Authority (NZ) Revision Year: 2022 Publisher: Pfizer New Zealand Ltd, PO Box 3998, Auckland, New Zealand, Toll Free number: 0800 736 363
DALACIN C 150 mg capsules.
| Pharmaceutical Form |
|---|
|
Capsules. The capsules consist of a white cap and white body imprinted with ‘Clin 150’ and ‘Pfizer’ in edible black ink. |
Each DALACIN C 150 mg capsule contains 177.515 mg clindamycin hydrochloride equivalent to 150 mg clindamycin.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Clindamycin |
Clindamycin is a lincosamide antibiotic with a primarily bacteriostatic action against Gram-positive aerobes and a wide range of anaerobic bacteria. Lincosamides such as clindamycin bind to the 50S subunit of the bacterial ribosome and inhibit the early stages of protein synthesis. |
| List of Excipients |
|---|
|
Lactose monohydrate Capsule shell: Titanium dioxide |
Blister packs of 16, 24 or 100 capsules*.
* Not all pack sizes available.
Pfizer New Zealand Ltd, PO Box 3998, Auckland, New Zealand, Toll Free number: 0800 736 363
24 August 1972
| Drug | Countries | |
|---|---|---|
| DALACIN-C | Austria, Australia, Brazil, Canada, Cyprus, Estonia, Hong Kong, Croatia, Ireland, Israel, Italy, Lithuania, Malta, Mexico, Netherlands, New Zealand, Poland, Romania, Singapore, United Kingdom, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
